The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

Cardiome Pharma Corp closed at $12.17.

Over the last five days, shares are unchanged, but have gained 13.95% over the last year to date. This security has outperformed the S&P TSX by 7.10% during the last year.

Key company metrics

  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield--
  • Trailing EPS-$1.56
Updated at previous session's close. Delayed by at least 15 minutes.


Net Profit (TTM)

Cardiome Pharma Corp has a net profit margin of -70.45%. Besides being negative, it is also below the industry average and implies that this company is not effective at turning revenues into bottom line profit.
Company Books

S&P TSX0.13%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201409/30/2014Jun 30, 201406/30/2014Mar 31, 201403/31/2014Dec 31, 201312/31/2013
Total other revenue--------
Total revenue8884
Gross profit5563
Total cost of revenue3211
Total operating expense11121011
Selling / general / administrative8987
Research & development0000
Depreciation / amortization1110
Interest expense (income), net operating--------
Unusual expense (income)0003
Other operating expenses, total--------
Operating income-3-4-3-8
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Income before tax-4-4-3-7
Income after tax-4-4-3-7
Income tax, total0000
Net income-4-4-3-7
Total adjustments to net income--------
Net income before extra. items-4-4-3-7
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-4-4-3-7
Inc. avail. to common incl. extra. items-4-4-3-7
Diluted net income-4-4-3-7
Dilution adjustment----00
Diluted weighted average shares17171514
Diluted EPS excluding extraordinary itemsvalue per share-0.26-0.26-0.20-0.53
Dividends per sharevalue per share0.
Diluted normalized EPSvalue per share-0.26-0.26-0.20-0.39